In cancer immunotherapy, the use of checkpoint inhibitors such as those that block the PD-1:PD-L1 pathway has resulted in significant clinical benefits with a wide range of cancer types including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) [32]. This evidence concerns the gene CD274 and renal cell carcinoma.